Mycotopia Therapies, Inc.
TPIA
Other OTC0.02
USD
+0.00
- -
Mycotopia Therapies, Inc.
TPIA
(Other OTC)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mycotopia Therapies, Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of plant-based psychedelic therapies and wellness products. The company’s product portfolio includes psychedelic-enhanced psychotherapeutics, pharmaceutical-grade cannabinoid products marketed under the RHO Phyto™ brand with controlled dosing formulations in oral, sublingual, topical, and transdermal delivery forms, and functional mushrooms-based natural health products. Mycotopia also offers pioneering medical psychedelics such as the Odyssey Elixir and Psilly patches, targeting treatment for mental health conditions such as anxiety, depression, bipolar disorder, PTSD, ADHD, autism, and addictions primarily in regulated markets including Jamaica, the Netherlands, and broader Europe. Founded in 2018 and headquartered in Miami, Florida, Mycotopia Therapies has recently undergone a strategic transition and rebranding, officially changing its name to AIBiotics, Inc. in early 2025, reflecting a broader shift towards integrating artificial intelligence technologies in health and wellness solutions. This transition includes the acquisition of Philon Labs, a company with patented AI robotics-based home health products such as the Phill Robot™ massage system and the MilkyWay breast milk storage system. Mycotopia’s partnerships include a strategic alliance with PsychedelicsEUROPE to advance psychedelic research and regulatory frameworks in Europe, and an expanded supply agreement with Havn Life Sciences to distribute a line of functional mushrooms and psilocybin-infused health products. Additionally, it collaborates with Ei.Ventures to form PSLY.COM, a combined entity focusing on botanical psychedelic APIs and therapeutics, leveraging the legal psilocybin markets in Jamaica and the Netherlands, with ambitions including expansion into digital markets and metaverse retail environments. These developments position Mycotopia Therapies as a diversified player in the psychedelic and wellness sectors, combining natural botanical medicine, pharmaceutical formulations, and cutting-edge AI robotics to address growing global mental health needs and consumer wellness trends.
Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT
AIBotics Provides 2025 Update; Strengthens Position in AI, Wellness, and Robotics
Mycotopia Therapies Acquires AI Robotics Assets with a Total Transaction Value of $9 Million
Psytech To Merge With Wesana; Mycotopia Shareholders Will Benefit From The Transactions